IPO TABLE: Five biotech offerings coming soon after Affimed priced, eight others filed or set terms
This article was originally published in Scrip
Executive Summary
The market for initial public offerings has been especially frothy for biotechnology companies during the past two years and the week of 15 to 19 September may illustrate perfectly the strange dichotomy at work in the IPO space.
You may also be interested in...
Finance Watch: Seed/Series A Financings Benefit As Big Crossover Rounds Slow
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates
ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment.
Finance Watch: SPACs Lose Their Luster As Difficulties Mount
Public Company Edition: While panelists at Biotech Showcase argued merging with a special purpose acquisition corporation is not as attractive as it used to be, firms continue to pursue this go-public alternative. Also, Hillstream launched a small IPO and Cytokinetics accessed cash from Royalty Pharma.